Author: admin

Metabolic Dysfunction-Associated Steatohepatitis Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Metabolic Dysfunction-Associated Steatohepatitis Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Metabolic Dysfunction-Associated Steatohepatitis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Metabolic dysfunction-associated steatohepatitis (MASH), historical and forecasted epidemiology as well as the Metabolic dysfunction-associated steatohepatitis (MASH) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Metabolic Dysfunction-Associated Steatohepatitis Market by downloading the comprehensive report from DelveInsight @ Metabolic Dysfunction-Associated Steatohepatitis Therapeutics Market

 

Key Takeaways from the Metabolic Dysfunction-Associated Steatohepatitis Market Report

• In August 2024:- Corcept Therapeutics- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH). Approximately 120 patients who are eligible for participation in the study will be randomized on Day 1 in a 2:1 ratio to 100 mg miricorilant or placebo twice weekly, for 48 weeks of treatment (Cohort A).
• In August 2024:- Regeneron Pharmaceuticals- This study is researching an investigational drug called ALN-HSD (called “study drug”). This study is focused on participants who are known to have non-alcoholic steatohepatitis (NASH). NASH is a form of non-alcoholic fatty liver disease (NAFLD). Recently, the name metabolic dysfunction associated steatohepatitis (MASH) has been introduced to replace NASH and metabolic dysfunction-associated steatotic liver disease (MASLD) to replace NAFLD. NASH occurs when fat builds up in liver cells, damaging them, and making the liver inflamed and stiff from fibrosis (scar tissue).
• The Metabolic Dysfunction-Associated Steatohepatitis Market Size in the 7MM will increase at a significant CAGR due to increasing prevalent cases of the disease and the launch of the emerging therapies.
• Based on DelveInsight’s estimates, the United States had the highest number of diagnosed prevalent cases of MASH in 2023, with a total of ~9.7 million cases. Following the US, EU4 and the UK had ~3.8 million cases, while Japan had ~2.6 million cases.
• The categorization based on gender, showed that diagnosed prevalent cases in males were higher than in females in the 7MM. The male-diagnosed prevalent cases accounted for 56% of the total cases in the 7MM.
• Japan accounted for approximately 16% of the total MASH Diagnosed Prevalent Cases in the 7MM in 2023. These cases are expected to increase in the study period (2020–2034).
• The leading MASH Companies such as Corcept Therapeutics, Aligos Therapeutics, Akero Therapeutics Inc., Regeneron Pharmaceuticals, Merck Sharp & Dohme LLC, 89Bio Inc., and others.
• Promising MASH Therapies such as Efinopegdutide, Efruxifermin, Pegozafermin, ALN-HSD, ALG-055009, Miricorilant, and others.

 

Gain a competitive edge in the Metabolic Dysfunction-Associated Steatohepatitis Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Metabolic Dysfunction-Associated Steatohepatitis Treatment Drugs

 

Metabolic Dysfunction-Associated Steatohepatitis Epidemiology Segmentation in the 7MM

• Metabolic Dysfunction-Associated Steatohepatitis Prevalent Cases
• Metabolic Dysfunction-Associated Steatohepatitis Diagnosed Prevalent Cases
• Metabolic Dysfunction-Associated Steatohepatitis Gender-specific Diagnosed Prevalent Cases
• Metabolic Dysfunction-Associated Steatohepatitis Severity-specific Diagnosed Prevalent Cases

 

Metabolic Dysfunction-Associated Steatohepatitis Market Insights

MASH is a condition in which fat builds up in liver. It is the most common chronic liver disease, affecting at least a quarter of the global adult population. MASH is the progressive form of MASLD associated with persistent liver cell injury leading to fibrosis and in a subset may progress to cirrhosis and end-stage liver disease.

 

Discover key developments and opportunities in the Metabolic Dysfunction-Associated Steatohepatitis Market. Click here to learn more from DelveInsight’s latest report @ Metabolic Dysfunction-Associated Steatohepatitis Market Size

 

Metabolic Dysfunction-Associated Steatohepatitis Treatment Market

MASH treatment market marks a significant milestone in medical advancements, revolutionizing the landscape of MASH treatment. REZDIFFRA has emerged as a breakthrough therapy specifically designed to target the underlying mechanisms of MASH, offering new hope to patients suffering from this debilitating condition. Clinical trials have demonstrated remarkable efficacy in reducing MASH symptoms such as inflammation and fibrosis, while also improving overall liver function and patient quality of life. This approval has provided healthcare providers with a powerful tool to combat MASH disease, filling a critical gap in treatment options and potentially reducing the burden of complications associated with advanced liver disease.

 

Metabolic Dysfunction-Associated Steatohepatitis Marketed Drugs

• REZDIFFRA (resmetirom): Madrigal Pharmaceuticals

REZDIFFRA is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). The emergence of the inaugural medication for MASH is a true game-changer for healthcare providers, the research community, and, most importantly, patients living with this serious liver condition. Based on the robust efficacy and safety data generated in two large Phase III MAESTRO studies, it is believed that REZDIFFRA will become the foundational therapy for patients with MASH with moderate to advanced liver fibrosis. As well as since now that the FDA has approved REZDIFFRA for MASH, pharmaceutical companies will have a better understanding of the thresholds they must meet to get future approvals.

 

Metabolic Dysfunction-Associated Steatohepatitis Emerging Drugs

• Pegozafermin: 89bio, Inc

Pegozafermin or BIO89-100 is a compound that specifically targets and activates a receptor known as fibroblast growth factor 21 (FGF21). FGF21 is a hormone involved in regulating glucose and lipid metabolism, and it has been shown to have potential therapeutic effects in MASH.

• Efruxifermin (EFX): Akero Therapeutics, Inc.

Efruxifermin (EFX), is Akero’s lead product candidate for MASH. It is a differentiated Fc-FGF21 fusion protein engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly SC dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treating MASH.

• Belapectin: Galectin Therapeutics

Belapectin a complex carbohydrate drug, targets galectin-3, a critical protein in fatty liver disease and fibrosis pathogenesis. Galectin-3 plays a major role in organ scarring diseases, including the liver, lung, kidney, heart, and vascular systems fibrotic disorders. The drug binds to galectin-3 proteins and disrupts its function.

 

Metabolic dysfunction-associated Steatohepatitis Market Outlook

Until mid-March, the therapeutic landscape of NASH lacked FDA, EMA, or PMDA-approved medications, relying primarily on lifestyle adjustments like diet and exercise. Supplemental interventions encompassed off-label usage of vitamin E and antidiabetic agents (e.g., pioglitazone, liraglutide) and liver transplantation in case of severe stages. Given NASH’s multifaceted pathogenesis, effective treatment demands comprehensive targeting of various cellular and molecular pathways.

 

Download DelveInsight’s Metabolic Dysfunction-Associated Steatohepatitis Market report today and stay ahead in this rapidly evolving field. @ Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials

 

Scope of the Metabolic Dysfunction-Associated Steatohepatitis Market Report

• Coverage- 7MM
• Metabolic Dysfunction-Associated Steatohepatitis Companies- Corcept Therapeutics, Aligos Therapeutics, Akero Therapeutics Inc., Regeneron Pharmaceuticals, Merck Sharp & Dohme LLC, 89Bio Inc., and others.
• MASH Therapies- Efinopegdutide, Efruxifermin, Pegozafermin, ALN-HSD, ALG-055009, Miricorilant, and others.
• Metabolic Dysfunction-Associated Steatohepatitis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Metabolic Dysfunction-Associated Steatohepatitis Unmet Needs, KOL’s views, Analyst’s views, Metabolic Dysfunction-Associated Steatohepatitis Market Access and Reimbursement

 

Download the report to understand which factors are driving Metabolic Dysfunction-Associated Steatohepatitis Market Trends @ Metabolic Dysfunction-Associated Steatohepatitis Market Trends

 

Table of Content

1. Key Insights

2. Report Introduction

3. Country-wise MASH Market Overview at a Glance

4. MASH Market Overview by Therapeutic Class

5. Methodology of MASH Epidemiology and Market

6. Executive Summary

7. Key Events

8. Disease Background and Overview

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Drugs

12. Emerging Drugs

13. MASH: Market Analysis

14. Key Opinion Leaders’ Views

15. SWOT Analysis

16. Unmet needs

17. Market Access and Reimbursement

18. Appendix

19. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 0650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metabolic Dysfunction-Associated Steatohepatitis Treatment Market Size in the 7MM was ~USD 1,700 Million in 2023, estimated DelveInsight

“Tendonitis Therapies such as TENDAXION, TENDOFIT, ZEPTIDE, TENACTIVE/TENDOACTIVE, TENDOMAC, RITISAL, and others”

 

The Tendonitis Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for o Tendonitis therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence

 

DelveInsight’s “Tendonitis Drugs Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Tendonitis, historical and forecasted epidemiology as well as the Tendonitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Unlock detailed insights into the Tendonitis Market by downloading the comprehensive report from DelveInsight @ Tendonitis Therapeutics Market

 

Key Takeaways from the Tendonitis Market Report

• The Growth of the Tendonitis Market is expected to be primarily driven by an expanding patient population, and advancement in diagnostic methods.
• The leading Tendonitis Companies such as MiMedex Group Inc, MEDRx USA Inc, Cerimon Pharmaceuticals, InGeneron Inc, ZetrOZ Inc, ZARS Pharma Inc, Smith & Nephew Inc., and others.
• Promising Tendonitis Therapies such as TENDAXION, TENDOFIT, ZEPTIDE, TENACTIVE/TENDOACTIVE, TENDOMAC, RITISAL, and others
• As per the DelveInsight estimates, the total Tendinopathy Gender-specific cases in the United States was ~8,499,400 and 3,642,600 cases for males and females, respectively in 2022, which are expected to grow during the study period, i.e., 2019–2032.
• In August 2024:- Wrightington, Wigan and Leigh NHS Foundation Trust- A Prospective, Double Blind, Single Centre, RCT, Comparing the Effectiveness of Physiotherapy in Addition to One of 3 Types of Image Guided Injection of the Common Extensor Tendon, on Pain and Function in Patients With Tennis Elbow.

 

Gain a competitive edge in the Tendonitis Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Tendonitis Treatment Drugs

 

Tendonitis Epidemiology Segmentation in the 7MM

• Total Tendonitis Incident Cases

• Tendonitis Type-specific Incident Cases

• Total Tendonitis Treated Cases

• Tendonitis Region-specific Incident Cases

• Tendonitis Gender-specific Incident Cases

 

Tendinopathy Treatment Market Landscape

The treatment landscape for tendinopathy is rapidly evolving, with numerous companies actively developing new therapies. Around 40-50% of patients currently undergo physiotherapy as part of their treatment. Recently, there’s been a surge in nutraceutical products that appear to support the healing of tendon injuries and may also serve as preventive measures. Although preclinical results are promising, the available literature on this topic remains limited. Managing tendinopathy with oral supplements is still a relatively new approach.

 

Tendinopathy Market Insights

Tendinopathy refers to a complex and multifaceted condition of the tendon, marked by pain, diminished function, and decreased exercise tolerance. The most frequently affected tendons due to overuse include the rotator cuff, medial and lateral elbow epicondyles, patellar, gluteal, and Achilles tendons. Key histological and molecular characteristics of tendinopathy include collagen fiber disorganization, increased microvasculature and sensory nerve innervation, disrupted extracellular matrix homeostasis, elevated immune cell activity and inflammatory mediators, and heightened cellular apoptosis.

 

Discover key developments and opportunities in the Tendonitis Market. Click here to learn more from DelveInsight’s latest report @ Tendonitis Market Size

 

Tendonitis Emerging Drugs

• SI-613: Seikagaku Corporation

SI-613 is a formulation in which hyaluronic acid and a non-steroidal anti-inflammatory drug (NSAID) are chemically bound using Seikagaku’s own proprietary technology. SI-613 was designed to provide pain relief and anti-inflammatory effect by sustained release of NSAID, and the joint function improving effect by hyaluronic acid. It is expected to provide prompt and sustained relief of the severe pain and inflammation associated with osteoarthritis and enthesopathy. The drug is currently in phase II of clinical trials for the treatment of Tendonitis.

• MP1032: MetrioPharm

MP1032’s mode of action – to accelerate the healing process – allows for the use of MP1032 as a therapeutic for Tendonitis before a tendinosis develops. In addition, MP1032 could accelerate the repair of already damaged tendons and thus also shorten the duration of tendinosis treatments. The drug is currently in phase I of clinical trials for the treatment of Tendonitis.

 

Tendinopathy Drugs and Companies

• OCS-05 IV administration: Oculis
•  BAT4406F Injection: Bio-Thera Solutions
• Ravulizumab: Alexion Pharmaceuticals
• B001: Shanghai Drug Research Development Co. Ltd.
• Inebilizumab: Hansoh BioMedical R&D Company

 

Tendinopathy Market Dynamics

The dynamics of the Tendinopathy market are expected to evolve in the coming years. Preclinical models have supported this emerging therapeutic approach, but there is a notable lack of clinical studies involving stem cells for enhancing tendon repair or treating Tendinopathy, especially when compared to scaffolds and growth factors.

 

Download DelveInsight’s Tendonitis Market report today and stay ahead in this rapidly evolving field. @ Tendonitis Clinical Trials

 

Scope of the Tendonitis Market Report

• Coverage- 7MM
• Tendonitis Companies- MiMedex Group Inc, MEDRx USA Inc, Cerimon Pharmaceuticals, InGeneron Inc, ZetrOZ Inc, ZARS Pharma Inc, Smith & Nephew Inc., and others.
• Tendonitis Therapies- TENDAXION, TENDOFIT, ZEPTIDE, TENACTIVE/TENDOACTIVE, TENDOMAC, RITISAL, and others
• Tendonitis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Tendonitis Unmet Needs, KOL’s views, Analyst’s views, Tendonitis Market Access and Reimbursement

 

Download the report to understand which factors are driving Tendonitis market trends @ Tendonitis Market Trends

 

Table of Content

1. Key Insights

2. Executive Summary of Tendonitis

3. Competitive Intelligence Analysis for Tendonitis

4. Tendonitis: Market Overview at a Glance

5. Tendonitis: Disease Background and Overview

6. Patient Journey

7. Tendonitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Tendonitis Treatment

11. Marketed Products

12. Emerging Therapies

13. Tendonitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Tendonitis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tendonitis Treatment Market Size in the 7MM is projected to experience growth during the Study Period (2020-2034)

Metastatic Prostate Cancer Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Metastatic Prostate Cancer Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the metastatic prostate cancer, historical and forecasted epidemiology as well as the metastatic prostate cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Metastatic Prostate Cancer Market by downloading the comprehensive report from DelveInsight @ Metastatic Prostate Cancer Therapeutics Market

 

Key Takeaways from the Metastatic Prostate Cancer Market Report

• In September 2024:- Bayer- The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer. A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer (mHSPC).
• The Metastatic Prostate Cancer Market Size in the 7MM will increase at a significant CAGR due to increasing prevalent cases of the disease and the launch of the emerging therapies.
• Based on DelveInsight’s assessment in 2023, the 7MM had approximately 240,300 prevalent cases of metastatic prostate cancer. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period (2024−2034).
• Around 45% of all metastatic prostate cancer cases are attributed for mCSPC and ~55% accounted for mCRPC.
• As per the estimates, in the US, majority of the cases were found to be localized/ locally advanced cases (Stage I-III), comprising approximately 60% of total cases, while nearly 32% belonged to biochemical recurrence/ progressive cases, and ~8% belonged to metastatic cases.
• Prostate cancer is most frequently diagnosed among men aged 65–74 years. Analysis indicates that age-specific data differs across various geographic regions. In the US, prostate cancer was least prevalent among individuals aged over 84 years, whereas in Japan, the lowest number of cases were observed in the age group of 54 years or younger.
• The leading Metastatic Prostate Cancer Companies such as AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, AstraZeneca, Seagen/Merck, Bristol Myers Squibb, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, and others
• Promising Metastatic Prostate Cancer Therapies such as ERLEADA (apalutamide), ORGOVYX (relugolix), JEVTANA (Cabazitaxel), XOFIGO (radium-223), ZYTIGA (abiraterone acetate), XTANDI (enzalutamide), NUBEQA (darolutamide), PLUVICTO (177Lu-PSMA-617), and others.

 

Gain a competitive edge in the Metastatic Prostate Cancer Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Metastatic Prostate Cancer Treatment Drugs

 

Metastatic Prostate Cancer Epidemiology Segmentation in the 7MM

• Total Prevalent Cases of Prostate Cancer in the US
• Total Diagnosed Prevalent Cases of Prostate Cancer in the US
• Age-specific Cases of Prostate cancer in the US
• Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the US
• Total Metastatic Cases of Prostate Cancer (mCSPC and mCRPC) in the US
• Total Treated Cases of mCRPC in the US

 

Metastatic Prostate Cancer Treatment Market

The Metastatic Prostate Cancer treatment market landscape encompasses a diverse array of therapeutic options, including PARP inhibitors, androgen receptor inhibitors, CYP17 inhibitors, microtubule inhibitors, ionizing radiation emitters, and others across various lines of treatment. The recent emergence of PARP inhibitors, particularly for patients harboring mutations in DNA damage repair genes, has expanded personalized treatment approaches and offered hope for improved outcomes.

 

Discover key developments and opportunities in the Metastatic Prostate Cancer Market. Click here to learn more from DelveInsight’s latest report @ Metastatic Prostate Cancer Market Size

 

Metastatic Prostate Cancer Marketed Drugs

• NUBEQA (darolutamide): Bayer

NUBEQA (darolutamide) is an oral androgen receptor inhibitor with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, inhibiting the receptor function and the growth of prostate cancer cells.

NUBEQA is indicated for treating adult patients with non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer in combination with docetaxel.

• ERLEADA (apalutamide): Janssen

ERLEADA is a next-generation oral androgen receptor inhibitor that blocks the androgen-signaling pathway in prostate cancer cells. ERLEADA inhibits the growth of cancer cells in three ways: by preventing the binding of androgen to the androgen receptor, by stopping the androgen receptor from entering the cancer cells, and by preventing the AR from binding to the DNA of the cancer cell. It is indicated for treating patients with non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer.

 

Emerging Metastatic Prostate Cancer Drugs

• MGC018 (vobramitamab duocarmazine): MacroGenics

MGC018 (vobramitamab duocarmazine) is an investigational ADC comprised of a humanized B7-H3 mAb conjugated via a cleavable linker to the prodrug Seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA). MacroGenics began enrolling the TAMARACK Phase II study of vobramitamab duocarmazine (vobra duo) in patients with mCRPC under an amended protocol during the second quarter. This study is designed to evaluate vobra duo at two different doses, 2.0 mg/kg or 2.7 mg/kg every 4 weeks, across 100 patients. MacroGenics is also evaluating the activity of MGC018 plus lorigerlimab (an investigational PD-1 × CTLA-4 bispecific DART® molecule) in a Phase 1 study in patients with advanced solid tumors.

• Bavdegalutamide (ARV-110): Arvinas

ARV-110 is an oral PROTAC protein degrader that targets the androgen receptor for potentially treating men with mCRPC and who have progressed on existing therapies. ARV-110 has demonstrated activity in preclinical models of androgen receptor mutation or overexpression, both common mechanisms of resistance to currently available androgen receptor-targeted therapies.

 

Metastatic Prostate Cancer Market Outlook

Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a stage of prostate cancer that has spread to other parts of the body, such as lymph nodes or bones, and no longer responds to treatment that lowers testosterone. Despite currently approved therapeutics, mCRPC remains a terminal diagnosis with an aggressive disease course. ADT is a stalwart therapy for the initial treatment of metastatic disease. Unfortunately, most men in this situation will go on to develop mCRPC and require secondary systemic therapy. This disease state can be very challenging to treat.

 

Download DelveInsight’s Metastatic Prostate Cancer Market report today and stay ahead in this rapidly evolving field. @ Metastatic Prostate Cancer Clinical Trials

 

Scope of the Metastatic Prostate Cancer Market Report

• Coverage- 7MM
• Metastatic Prostate Cancer Companies- AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, AstraZeneca, Seagen/Merck, Bristol Myers Squibb, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, and others
• Metastatic Prostate Cancer Therapies- ERLEADA (apalutamide), ORGOVYX (relugolix), JEVTANA (Cabazitaxel), XOFIGO (radium-223), ZYTIGA (abiraterone acetate), XTANDI (enzalutamide), NUBEQA (darolutamide), PLUVICTO (177Lu-PSMA-617), and others.
• Metastatic Prostate Cancer Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Metastatic Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Prostate Cancer Market Access and Reimbursement

 

Download the report to understand which factors are driving Metastatic Prostate Cancer Market Trends @ Metastatic Prostate Cancer Market Trends

 

Table of Content

1 Key Insights

2 Report Introduction

3 Executive Summary of Prostate Cancer

4 Key Events

5 Epidemiology and Market Forecast Methodology

6 Prostate Cancer Market Overview at a Glance

7 Disease Background and Overview

8 Treatment and Management of Prostate Cancer

9 Treatment Guidelines

10 Epidemiology and Patient Population

11 Patient Journey

12 Marketed Therapies

13 Emerging Therapies

14 Prostate Cancer: Seven Major Market Analysis

15 Unmet Needs

16 SWOT Analysis

17 KOL Views

18 Market Access and Reimbursement

19 Appendix

20 DelveInsight Capabilities

21 Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Prostate Cancer Treatment Market Size is expected to grow with a significant CAGR during the study period (2020-2034)

Parainfluenza Virus Infection Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Parainfluenza Virus Infection Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Parainfluenza Virus Infection Market Insight, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of parainfluenza virus infection, historical and forecasted epidemiology as well as parainfluenza virus infection market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Parainfluenza Virus Infection Market by downloading the comprehensive report from DelveInsight @ Parainfluenza Virus Infection Therapeutics Market

 

Key Takeaways from the Parainfluenza Virus Infection Market Report

• As per DelveInsight analysis, it is estimated that the Parainfluenza Virus Infection treatment market will experience significant changes during the forecast period of 2024–2034, owing to the launch of new therapies that are in clinical development for the treatment of Parainfluenza Virus Infection Market Size and due to the increasing patient pool.
• According to DelveInsight’s analysis in 2023, there were approximately 2,709,923 total incident cases of Parainfluenza Virus Infection in the 7MM. These cases are expected to increase by 2034 at a significant CAGR during the study period (2020–2034).
• In 2023, the US accounted for approximately 1,456,399 incident cases of Parainfluenza Virus Infection. These cases are further expected to increase during the study period (2020-2034).
• In 2023, Spain recorded the highest number of incident cases of PIV among EU4 and the UK, with nearly 257,254 cases. Germany followed with approximately 234,811 cases, while France reported around 190,245 cases. The incidence of Parainfluenza Virus Infection is projected to rise further during the forecast period.
• The leading Parainfluenza Virus Infection Companies such as ModernaTX Inc., MedImmune LLC, Ansun Biopharma Inc., AlloVir, CyanVac LLC, QIAGEN Gaithersburg Inc., Novartis, Pfizer, Brazion Therapeutics, and others.
• Promising Parainfluenza Virus Infection Therapies such as DAS181, ALVR106, and others.

 

Gain a competitive edge in the Parainfluenza Virus Infection Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Parainfluenza Virus Infection Treatment Drugs

 

Parainfluenza Virus Infection Prevalence

• Total Incident Cases
• Serotype-Specific Incident Cases
• Gender-specific Incident Cases
• Age-specific Incident Cases

 

Parainfluenza Virus Infection Market Insights

Most cases of PIV infections tend to resolve without requiring targeted medical treatment. Nonetheless, supportive strategies such as adequate rest, hydration, and the use of over-the-counter medications to relieve symptoms may be recommended. In severe cases or among individuals with weakened immune systems, antiviral medications or hospitalization may be necessary. Additionally, Ribavirin is sometimes administered off-label for treating PIV infections due to its in vitro activity. However, its effectiveness is subject to debate, as there is a lack of data from randomized trials.

 

Discover key developments and opportunities in the Parainfluenza Virus Infection Market. Click here to learn more from DelveInsight’s latest report @ Parainfluenza Virus Infection Market Size

 

Parainfluenza Virus Infection Treatment Market

The Parainfluenza Virus Infection Treatment Market addresses the growing demand for therapies that manage and mitigate infections caused by the human parainfluenza viruses (HPIVs). These viruses are a leading cause of respiratory illnesses, particularly in young children, the elderly, and immunocompromised individuals. While HPIVs can cause mild cold-like symptoms in some, they are known to lead to more severe conditions such as croup, bronchiolitis, and pneumonia.

 

Parainfluenza Virus Infection Market Outlook

The parainfluenza virus infection market outlook is expected to grow as the demand for more effective treatments and preventive measures continues to rise. Companies investing in novel antiviral therapies, immunotherapies, and vaccine research are likely to see significant opportunities in the coming years. Additionally, collaborations between pharmaceutical firms, research institutions, and government bodies may accelerate advancements in this field.

 

Download DelveInsight’s Parainfluenza Virus Infection Market report today and stay ahead in this rapidly evolving field. @ Parainfluenza Virus Infection Clinical Trials

 

Scope of the Parainfluenza Virus Infection Market Report

• Coverage- 7MM
• Parainfluenza Virus Infection Companies- ModernaTX Inc., MedImmune LLC, Ansun Biopharma Inc., AlloVir, CyanVac LLC, QIAGEN Gaithersburg Inc., Novartis, Pfizer, Brazion Therapeutics, and others.
• Parainfluenza Virus Infection Therapies- DAS181, ALVR106, and others.
• Parainfluenza Virus Infection Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Parainfluenza Virus Infection Unmet Needs, KOL’s views, Analyst’s views, Parainfluenza Virus Infection Market Access and Reimbursement

 

Download the report to understand which factors are driving Parainfluenza Virus Infection Market Trends @ Parainfluenza Virus Infection Market Trends

 

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Parainfluenza Virus Infection (PIV) Market Overview at a Glance

5. Key Events

6. Epidemiology and Market Forecast Methodology

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Emerging Therapies

11. Parainfluenza Virus Infection (PIV): Seven Major Market Analysis

12. Unmet Needs

13. SWOT Analysis

14. KOL Views

15. Reimbursement and Market Access

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parainfluenza Virus Infection Treatment Market Size in the 7MM was ~USD 360 Million in 2023, estimates DelveInsight

Sarcoidosis Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Sarcoidosis Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Sarcoidosis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Sarcoidosis, historical and forecasted epidemiology as well as the Sarcoidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Unlock detailed insights into the Sarcoidosis Market by downloading the comprehensive report from DelveInsight @ Sarcoidosis Therapeutics Market

 

Key Takeaways from the Sarcoidosis Market Report

• The Sarcoidosis Market Size in the 7MM will increase at a significant CAGR due to increasing prevalent cases of the disease and the launch of the emerging therapies.
• According to DelveInsight’s analysts, there were ~8 thousand diagnosed prevalent cases of Sarcoidosis in Japan in 2023, and this number is expected to change by 2034.
• The Diagnosed Prevalent cases of Sarcoidosis were highest in the US compared to the other 7MM countries. In 2023, the total Diagnosed Prevalent cases of Sarcoidosis in the US were 158 thousand cases which are anticipated to increase at a significant CAGR during the forecasted period (2024–2034).
• In the EU4 and the UK countries, the diagnosed prevalent population of Sarcoidosis was maximum in Germany with 29 thousand cases, followed by the Italy with 25 thousand cases in 2023. While the least number of cases were in Spain, with 4 thousand cases in 2023.
• Among the 7MM, EU4 and the UK accounted for approximately 34% of Diagnosed Prevalent cases of Sarcoidosis in 2023.
• The leading Sarcoidosis Companies such as Relief Therapeutics Holdings, aTyr Pharma, Amgen, Bristol-Myers Squibb, Novartis, Pfizer, United Therapeutics Corporation, and others.
• Promising Sarcoidosis Therapies such as OFEV (nintedanib), KRP-R120, XTMAB-16, OATD-01, and others.

 

Gain a competitive edge in the Sarcoidosis Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Sarcoidosis Treatment Drugs

 

Sarcoidosis Epidemiology

Sarcoidosis is an inflammatory disease characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organs of the body. When left unchecked, chronic inflammation can lead to fibrosis, the permanent scarring of organ tissue. Sarcoidosis most commonly affects the lungs and lymph nodes, but it can also affect the eyes, skin, heart, and nervous system. Sarcoidosis-associated pulmonary hypertension (SAPH) is a recognized complication of advanced pulmonary sarcoidosis and is a significant cause of morbidity and mortality in sarcoidosis. It is classified as WHO group V Pulmonary hypertension because of its multifactorial mechanisms. Clinical presentations of sarcoidosis are diverse, ranging from asymptomatic, incidental findings to organ failure. However, common symptoms typically include tender, red bumps on the skin, shortness of breath, and a persistent cough.

 

Sarcoidosis Market Insights

Sarcoidosis is an inflammatory disease that primarily affects the lungs but can involve multiple organs, including the skin, eyes, heart, and lymph nodes. Treatment of sarcoidosis depends on the severity of the disease, the organs affected, and the individual patient’s symptoms. Not all patients require treatment, as the disease may resolve on its own. For those who do require medical intervention, treatment aims to manage symptoms, control inflammation, and prevent complications.

 

Sarcoidosis Emerging Drugs Profile

• KRP-R120: Kyorin Pharmaceutical Co. Ltd/ aTyr Pharma
• XTMAB-16: Xentria, Inc.
• OATD-01: Molecure S.A.

 

Discover key developments and opportunities in the Sarcoidosis Market. Click here to learn more from DelveInsight’s latest report @ Sarcoidosis Market Size

 

Sarcoidosis Treatment Market

The Sarcoidosis Treatment Market is gaining attention due to advancements in therapies targeting this rare inflammatory disease, which primarily affects the lungs and lymph nodes. Sarcoidosis results in the growth of tiny clumps of inflammatory cells (granulomas) in different parts of the body, and the cause remains largely unknown. The condition can be asymptomatic, but in severe cases, it may require aggressive treatment to prevent organ damage.

 

Sarcoidosis Market Drivers

The Sarcoidosis Market is driven by the increasing awareness and diagnosis rates of sarcoidosis, advancements in therapeutic options, and a growing demand for effective treatments. As the disease often requires long-term management, the need for chronic therapies is also fueling the market. Major pharmaceutical companies are focusing on developing novel treatment options, including immunosuppressants and biologics, to address the unmet medical needs in this space.

 

Download DelveInsight’s Sarcoidosis Market report today and stay ahead in this rapidly evolving field. @ Sarcoidosis Clinical Trials

 

Scope of the Sarcoidosis Market Report

• Coverage- 7MM
• Sarcoidosis Companies- Relief Therapeutics Holdings, aTyr Pharma, Amgen, Bristol-Myers Squibb, Novartis, Pfizer, United Therapeutics Corporation, and others.
• Sarcoidosis Therapies- OFEV (nintedanib), KRP-R120, XTMAB-16, OATD-01, and others.
• Sarcoidosis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Sarcoidosis Unmet Needs, KOL’s views, Analyst’s views, Sarcoidosis Market Access and Reimbursement

 

Download the report to understand which factors are driving Sarcoidosis Market Trends @ Sarcoidosis Market Trends

 

Table of Content

1. Key Insights

2. Executive Summary of Sarcoidosis

3. Competitive Intelligence Analysis for Sarcoidosis

4. Sarcoidosis: Market Overview at a Glance

5. Sarcoidosis: Disease Background and Overview

6. Patient Journey

7. Sarcoidosis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Sarcoidosis Unmet Needs

10. Key Endpoints of Sarcoidosis Treatment

11. Sarcoidosis Marketed Products

12. Sarcoidosis Emerging Therapies

13. Sarcoidosis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Sarcoidosis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sarcoidosis Treatment Market Size in the 7MM was ~USD 828 million in 2023, estimates DelveInsight

The Type 2 Diabetes Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Type 2 Diabetes Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Type 2 Diabetes, historical and forecasted epidemiology as well as the Type 2 Diabetes market trends in the United States, EU4 (Germany, Spain, Italy, France), and the United Kingdom, and Japan.

 

Unlock detailed insights into the Type 2 Diabetes Market by downloading the comprehensive report from DelveInsight @ Type 2 Diabetes Therapeutics Market

 

Key Takeaways from the Type 2 Diabetes Market Report

• The Type 2 Diabetes Market Size in the 7MM will increase at a significant CAGR due to increasing prevalent cases of the disease and the launch of the emerging therapies.
• In September 2024:- Novo Nordisk A/S- The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
• As per the analysis, the risk of type 2 diabetes increases with age, especially after 45, because people tend to exercise less and gain weight.
• According to Diabetes UK, in 2018, 12.3 million people in the UK were at risk of developing type 2 diabetes due to their lifestyle.
• According to the American Diabetes Association (2024), in adults with type 2 diabetes who have not achieved their individualized weight goals, additional weight management interventions (e.g., intensification of lifestyle modifications, structured weight management programs, pharmacologic agents, or metabolic surgery, as appropriate) are recommended.
• According to the CDC, 4.6 to 9.2 percent of pregnancies may be affected by gestational diabetes. In up to 10 percent of them, the mother is diagnosed with type 2 diabetes just after the pregnancy. The rest of these women have a 35 to 60 percent chance of developing type 2 diabetes within 10 to 20 years.
• The leading Type 2 Diabetes Companies such as Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide, Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., and others 
• Promising Type-2 Diabetes Therapies such as NRDN-101, ECC5004, KN056, XW014, RGT001-075, HR17031, CPL207280, THDB0206, LY-3209590, Insulin icodec, and others.

 

Gain a competitive edge in the Type 2 Diabetes Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Type 2 Diabetes Treatment Drugs

 

Type 2 Diabetes Prevalence

• Total Type 2 Diabetes Prevalent Cases
• Total Type 2 Diabetes Diagnosed Prevalent Cases
• Total Type 2 Diabetes Gender-specific Cases
• Total Type 2 Diabetes Age-specific Cases
• Type 2 Diabetes Treated Cases

 

Type 2 Diabetes Treatment Market

The primary treatment for type 2 diabetes includes lifestyle changes, such as diet and exercise, alongside approved therapies like metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin. Recent advancements include the approval of BRENZAVVY by TheracosBio in 2023 and TWYMEEG by Sumitomo Pharma/Poxel in 2021, which enhance treatment options and glucose management.Focusing on the chronic and severe nature of TD1 and TD2, the treatment approach for them is quite comprehensive; regularization of glucose metabolism and control of risk factors (e.g., arterial hypertension) is the key treatment target for type 2 diabetes. Metformin, which is the most commonly prescribed initial treatment for the condition, lowers blood sugar levels for patients by improving how their body handles insulin. Many other therapies including Alpha-glucosidase inhibitors, Amylin analogs, or agonists and sodium-glucose cotransporter-2 inhibitors, etc. are prescribed to treat type 2 diabetes.

 

Type 2 Diabetes Market Insights

Type 2 diabetes is a serious, life-threatening condition with no cure, serving as a risk factor for numerous other disorders. While there is no established cure, devices are available to monitor glucose levels, and treatment involves both oral and injectable medications, alongside lifestyle changes like a healthy diet and regular exercise. Metformin, the most commonly prescribed initial treatment, improves insulin sensitivity to lower blood sugar. Alpha-glucosidase inhibitors (AGIs), such as Glucobay (acarbose) and Glyset (miglitol), delay carbohydrate absorption, reducing post-meal glucose spikes and HbA1c levels. Amylin analogs, like Symlin, are injectable drugs that promote weight loss and help control glucose but require careful monitoring to prevent hypoglycemia. Novo Nordisk’s SAXENDA (liraglutide) helps manage T2D by improving glycemic control, promoting weight loss, enhancing β-cell function, and reducing HbA1c levels.

 

Discover key developments and opportunities in the Type 2 Diabetes Market. Click here to learn more from DelveInsight’s latest report @ Type 2 Diabetes Market Size

 

Type 2 Diabetes Marketed Drugs

• Rybelsus: Novo Nordisk

In September 2019, the US Food and Drug Administration approved Rybelsus (semaglutide) oral tablets to improve the control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise. Rybelsus is the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the United States that does not need to be injected. GLP-1 drugs are non-insulin treatments for people with type 2 diabetes.

• Trijardy XR: Eli Lilly and Boehringer Ingelheim

In January 2020, the US FDA approved Trijardy XR to lower blood sugar in adults with type 2 diabetes, along with diet and exercise. Trijardy XR provides three type 2 diabetes medicines in one pill, including Jardiance (empagliflozin), Tradjenta (linagliptin) and metformin hydrochloride extended-release. In the US, both Jardiance and Tradjenta are once-daily tablets used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. The drug is being marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company

 

Type 2 Diabetes Emerging Drugs

• Danuglipron (PF-06882961) – Pfizer

Danuglipron (PF-06882961), an oral small-molecule, GLP-1R agonist being developed by Pfizer. The drug is currently in Phase II of development. In Phase I, danuglipron demonstrated robust reductions in fasting plasma glucose of -66.6, -80.6, and -89.7 mg/dL at doses of 15, 70, and 120 mg respectively, compared to a -24.8 mg/dL reduction for placebo. Danuglipron also reduced HbA1c by -0.9, -1.2, and -1.2% at doses of 15, 70 and 120 mg respectively, compared to a -0.4% reduction for placebo-treated subjects. The results with the highest dose tested in a phase 2 trial show promising HbA1c lowering and weight loss.

• ORMD-0801- Oramed

Oramed’s oral insulin ORMD-0801 is a Phase III drug has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. The drug is being evaluated in two Phase III trials ORA-D-013-1 and ORA-D-013-2 with the company anticipating the approval in 2024. Other Noverl emerging drugs in teh Type-2 Diabetes treatment market in teh different clinical trials phases include – Research programme: type 2 diabetes mellitus therapeutics: Abarceo Pharma, NRDN-101: Neurodon, ECC5004: Eccogene, KN056: Suzhou Alphamab Co., Ltd., XW014: Sciwind Biosciences, RGT001-075: Regor Pharmaceuticals, HR17031: Jiangsu Hengrui Medicine Co, CPL207280: Celon Pharma, THDB0206: Tonghua Dongbao Pharmaceutical, LY-3209590: Eli Lilly and Company, Insulin icodec: Novo Nordisk, and others.

 

Type 2 Diabetes Market Outlook

The Type 2 diabetes Market is a crowded and competitive landscape with multiple, generic, and biosimilar drugs entering the market. The diabetes drugs market is moderately fragmented, with few significant and generic players. The market competitors are launching not only novel pharmaceuticals and therapies but also equipment and tools that can be used in the treatment and diagnosis of type 2 diabetes. The expansion of the healthcare sector and favorable government regulations are fueling the growth of the type 2 diabetes market.

 

Download DelveInsight’s Type 2 Diabetes Market report today and stay ahead in this rapidly evolving field. @ Type 2 Diabetes Clinical Trials

 

Scope of the Type 2 Diabetes Market Report

• Coverage- 7MM
• Type 2 Diabetes Companies- Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide, Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., and others.
• Type 2 Diabetes Therapies- NRDN-101, ECC5004, KN056, XW014, RGT001-075, HR17031, CPL207280, THDB0206, LY-3209590, Insulin icodec, and others.
• Type 2 Diabetes Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Type 2 Diabetes Unmet Needs, KOL’s views, Analyst’s views, Type 2 Diabetes Market Access and Reimbursement

 

Download the report to understand which factors are driving Type 2 Diabetes Market Trends @ Type 2 Diabetes Market Trends

 

Table of Content

1. Report Introduction

2. Executive Summary of Type 2 Diabetes

3. SWOT Analysis of Type 2 Diabetes

4. Type 2 Diabetes: Patient Share (%) Overview at a Glance

5. Type 2 Diabetes: Market Overview (%) at a Glance

6. Disease Background and Overview

7. Type 2 Diabetes Epidemiology and Patient Population

8. Country-Specific Patient Population of Type 2 Diabetes

9. Current Type 2 Diabetes Treatment and Medical Practices

10. Type 2 Diabetes Patient Journey

11. Type 2 Diabetes Unmet Needs

12. Key Endpoint of Clinical Trials

13. Type 2 Diabetes Marketed Products

14. Emerging Type 2 Diabetes Therapies

15. Conjoint Analysis of Type 2 Diabetes Therapies

16. Type 2 Diabetes: Market Size of 7MM

17. Country-Wise Market Analysis (2020–2034)

18. Market Access and Reimbursement of Drug induced dyskinesia

19. Type 2 Diabetes Market drivers

20. Type 2 Diabetes Market barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Type 2 Diabetes Treatment Market Size is expected to grow with a significant CAGR during the study period (2020-2034)

“Gastroenteropancreatic Neuroendocrine Tumors Therapies such as LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (Lanreotide), ITM-11, CAM2029 (Octreotide subcutaneous depot), and others”

 

The Gastroenteropancreatic Neuroendocrine Tumors market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Gastroenteropancreatic Neuroendocrine Tumors therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Gastroenteropancreatic Neuroendocrine Tumors Market Insight, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Gastroenteropancreatic Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Gastroenteropancreatic Neuroendocrine Tumors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Gastroenteropancreatic Neuroendocrine Tumors Market by downloading the comprehensive report from DelveInsight @ Gastroenteropancreatic Neuroendocrine Tumors Therapeutics Market

 

Key Takeaways from the Gastroenteropancreatic Neuroendocrine Tumors Market Report

• The Gastroenteropancreatic Neuroendocrine Tumors Market is expected to increase by the major drivers such as rising incident population, technological advancements, increased funding for new drug development and clinical trials, during the forecast period [2024–2034]
• The leading Gastroenteropancreatic Neuroendocrine Tumors Companies such as Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limited, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc., Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, and others.
• Promising Gastroenteropancreatic Neuroendocrine Tumors Therapies such as LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (Lanreotide), ITM-11, CAM2029 (Octreotide subcutaneous depot), and others
• As per DelveInsight’s assessments, the incidence of functional GEP-NET is more than that of nonfunctional GEPNET in the United States
• According to Dasari et al. (2017), the incidence rate of GEP-NETs in the United States was 3.56 cases per 100,000. Incidence rates of small intestinal, rectal, and pancreatic NETs were 1.05 cases per 100,000, 1.04 cases per 100,000, and 0.48 cases per 100,000, respectively. v According to Scherubl et al. (2013), the crude incidence rate of GEP NETs in Germany rose from 0.45 cases per 100,000 in 1976 to 2.5 cases per 100,000 in 2006.
• As per Masui et al. (2020), the age-adjusted overall incidence of gastro-entero-pancreatic neuroendocrineneoplasms (GEP-NEN) in Japan was 3.53 per 100,000.Most NENs in the esophagus or lungs were neuroendocrine carcinomas (NECs), while the majority of those in the duodenum, ileum, appendix and rectum were grade 1 neuroendocrine tumors (NETs).
• As per Genus et al. (2019), among the 15,222 cases of NET diagnosed between 2013 and 2015, 50.7% were diagnosed with GEP-NENs, this patient cohort included both NETs and NECs, with the latter comprising 37% of all patients.
• August 2024:- ITM Solucin GmbH- The purpose of the study is to evaluate the efficacy, safety & patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.
• August 2024:- RayzeBio, Inc.- Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy

 

Gain a competitive edge in the Gastroenteropancreatic Neuroendocrine Tumors Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Gastroenteropancreatic Neuroendocrine Tumors Treatment Drugs

 

Gastroenteropancreatic Neuroendocrine Tumors Treatment Market

Gastroenteropancreatic Neuroendocrine Tumors treatments usually induce tumor stabilization for a limited length of time. Enormous effort is being put into developing novel approaches to overcome treatment-related resistance in patients with advanced and progressive GEP-NETs. The relatively small number of patients included in clinical studies, as well as the relatively slow course of the disease, make it difficult to evaluate the response rates for new therapies and their influence on survival.

 

Gastroenteropancreatic Neuroendocrine Tumors Marketed Drugs

• LUTATHERA: Novartis
• SOMATULINE DEPOT: Ipsen Biopharmaceuticals

 

Gastroenteropancreatic Neuroendocrine Tumors Emerging Drugs

• CAM2029: Camurus AB
• ITM-11: ITM Isotope Technologies Munich

 

Discover key developments and opportunities in the Gastroenteropancreatic Neuroendocrine Tumors Market. Click here to learn more from DelveInsight’s latest report @ Gastroenteropancreatic Neuroendocrine Tumors Market Size

 

Gastroenteropancreatic Neuroendocrine Tumors Drugs and Companies

• ITM-11: ITM Isotope Technologies Munich
• CAM2029: Camurus
• RYZ101: RayzeBio
• Lanreotide: Merck Sharp & Dohme
• arginine/lysine: Advanced Accelerator
• Temozolomide (TMZ): Ipsen
• Lutetium (177Lu) Oxodotreotide Injection: Jiangsu HengRui Medicine
• RYZ101: RayzeBio, Inc.
• CAM2029: Camurus AB
• Everolimus: Novartis
• PEN-221: Tarveda Therapeutics
• Lutathera: Progenics Pharmaceuticals
• Ibrutinib: Pharmacyclics

 

Gastroenteropancreatic Neuroendocrine Tumors Therapeutics Market

The Gastroenteropancreatic Neuroendocrine Tumors therapeutics market is further expected to increase by the major drivers such as rising incident population, technological advancements, increased funding for new drug development and clinical trials, increasing awareness among common people, increasing research activities and upcoming therapies in the forecast period [2024– 2034]

 

Download DelveInsight’s Gastroenteropancreatic Neuroendocrine Tumors Market report today and stay ahead in this rapidly evolving field. @ Gastroenteropancreatic Neuroendocrine Tumors Clinical Trials

 

Scope of the Gastroenteropancreatic Neuroendocrine Tumors Market Report

• Coverage- 7MM
• Gastroenteropancreatic Neuroendocrine Tumors Companies- Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limited, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc., Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, and others.
• Gastroenteropancreatic Neuroendocrine Tumors Therapies- LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (Lanreotide), ITM-11, CAM2029 (Octreotide subcutaneous depot), and others.
• Gastroenteropancreatic Neuroendocrine Tumors Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs, KOL’s views, Analyst’s views, Gastroenteropancreatic Neuroendocrine Tumors Market Access and Reimbursement

 

Download the report to understand which factors are driving Gastroenteropancreatic Neuroendocrine Tumors Market trends @ Gastroenteropancreatic Neuroendocrine Tumors Market Trends

 

Table of Content

1. Key Insights

2. Report Introduction

3. Gastroenteropancreatic Neuroendocrine Tumors Market Overview at a Glance

4. Executive Summary of Gastroenteropancreatic Neuroendocrine Tumors

5. Disease Background and Overview

6. Methodology

7. Epidemiology and Patient Population

8. Patient Journey

9. Marketed Drugs

10. Emerging Drugs

11. GEP-NET: Seven Major Market Analysis

12. KOL Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access and Reimbursement

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastroenteropancreatic Neuroendocrine Tumors Treatment Market across the 7MM is projected to experience growth during the Study period (2020–2034)

“Smoking Cessation and Nicotine Addiction Therapies such as CHANTIX/ CHAMTIX (varenicline), ZYBAN (bupropion), Cytisinicline (cytisine), NFL-101, EMB-001 and others” 

 

The Smoking Cessation and Nicotine Addiction Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Smoking Cessation and Nicotine Addiction Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s ‘Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology, and Market Forecast–2034’ report delivers an in-depth understanding of the Smoking Cessation and Nicotine Addiction historical and forecasted epidemiology as well as the Smoking Cessation and Nicotine Addiction Market Trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

Unlock detailed insights into the Smoking Cessation and Nicotine Addiction Market by downloading the comprehensive report from DelveInsight @ Smoking Cessation and Nicotine Addiction Therapeutics Market

 

Key Takeaways from the Smoking Cessation and Nicotine Addiction Market Report

• The Smoking Cessation and Nicotine Addiction Market Size in the 7MM will increase at a significant CAGR due to increasing prevalent cases of the disease and the launch of the emerging therapies.
• According to DelveInsight estimates, EU4 and the UK accounted for approximately 63,953 thousand cases, which was the highest prevalent cases of tobacco use, followed by the US with around 50,886 thousand cases, and Japan with around 20,185 thousand cases in 2023. These cases are expected to decrease in the US, EU4 the UK, and Japan by 2034.
• Among the EU4 and the UK, Germany had the highest prevalent cases of tobacco use (approximately 18,101 thousand cases), followed by France (approximately 16,429 thousand cases) in 2023. On the other hand, the UK (8,788 thousand cases) had the lowest prevalent cases of tobacco use in EU4 and the UK countries and the 7MM.
• Tobacco use has been identified as male-dominant; in our analysis, the number of males suffering was higher than females. In 2023, ~59% of prevalent cases tobacco use of were of males, while ~41% of cases were of females in the 7MM
• The leading Smoking Cessation and Nicotine Addiction Companies such as Achieve Life Sciences, NFL Biosciences SAS, and others.
• Promising Smoking Cessation and Nicotine Addiction Therapies such as CHANTIX/ CHAMTIX (varenicline), ZYBAN (bupropion), Cytisinicline (cytisine), NFL-101, EMB-001, and others.

 

Gain a competitive edge in the Smoking Cessation and Nicotine Addiction Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Smoking Cessation and Nicotine Addiction Treatment Drugs

 

Smoking Cessation and Nicotine Addiction Treatment Market

Effective treatment for smoking cessation and nicotine addiction involves a multifaceted approach combining pharmacotherapy, behavioral therapy, and support systems. Pharmacotherapeutic options include nicotine replacement therapies (NRTs) like patches, gums, and lozenges, which help reduce withdrawal symptoms and cravings by delivering controlled doses of nicotine. Medications such as varenicline and bupropion act on neural pathways to diminish the pleasure derived from smoking and alleviate withdrawal effects. Behavioral therapies, including cognitive-behavioral therapy (CBT) and motivational interviewing, address the psychological aspects of addiction by helping individuals develop coping strategies, set goals, and enhance motivation to quit. Support systems, such as counseling, support groups, and helplines, provide continuous encouragement and resources, significantly improving quit rates. Combining these treatments increases the likelihood of successful smoking cessation by addressing both the physiological and psychological components of nicotine addiction.

 

Smoking Cessation and Nicotine Addiction Market Outlook

There are effective treatments that support tobacco cessation, including both behavioral therapies and FDA-approved medications. Several distinct products and services are available today for smoking cessation, alongside smoking alternatives that are not specifically indicated for cessation. FDA-approved pharmacotherapies include various forms of nicotine replacement therapies (NRTs) in the form of transdermal patches, gums, nasal sprays, oral inhalers, and lozenges.

 

 Smoking Cessation and Nicotine Addiction Marketed Drugs

• CHANTIX/ CHAMTIX (varenicline): Pfizer
• ZYBAN (bupropion): GlaxoSmithKline

 

Discover key developments and opportunities in the Smoking Cessation and Nicotine Addiction Market. Click here to learn more from DelveInsight’s latest report @ Smoking Cessation and Nicotine Addiction Market Size

 

Smoking Cessation and Nicotine Addiction Emerging Drugs

• Cytisinicline (cytisine): Achieve Life Sciences
• NFL-101: NFL Biosciences SAS
• EMB-001: Embera NeuroTherapeutics, Inc.

 

Smoking Cessation and Nicotine Addiction Market Dynamics

Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Axsome Therapeutics, Achieve Life Sciences, Chronic Airway Therapeutics, etc., are developing therapies for the treatment of Smoking Cessation and Nicotine Addiction.

 

Download DelveInsight’s Smoking Cessation and Nicotine Addiction Market report today and stay ahead in this rapidly evolving field. @ Smoking Cessation and Nicotine Addiction Clinical Trials

 

Scope of the Smoking Cessation and Nicotine Addiction Market Report

• Coverage- 7MM
• Smoking Cessation and Nicotine Addiction Companies- Achieve Life Sciences, NFL Biosciences SAS, and others.
• Smoking Cessation and Nicotine Addiction Therapies- CHANTIX/ CHAMTIX (varenicline), ZYBAN (bupropion), Cytisinicline (cytisine), NFL-101, EMB-001, and others.
• Smoking Cessation and Nicotine Addiction Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Smoking Cessation and Nicotine Addiction Unmet Needs, KOL’s views, Analyst’s views, Smoking Cessation and Nicotine Addiction Market Access and Reimbursement

 

Download the report to understand which factors are driving Smoking Cessation and Nicotine Addiction Market Trends @ Smoking Cessation and Nicotine Addiction Market Trends

 

Table of Content

1 Key Insights

2 Report Introduction

3 Smoking Cessation and Nicotine Addiction Market Overview at a Glance

4 Epidemiology and Market Forecast Methodology

5 Key Events

6 Executive Summary of Smoking Cessation and Nicotine Addiction

7 Smoking Cessation and Nicotine Addiction: Disease Background and Overview

8 Epidemiology and Patient Population of Smoking Cessation and Nicotine Addiction

9 Patient Journey

10 Marketed Drugs

11 Emerging Drugs

12 Smoking Cessation and Nicotine Addiction: Seven Major Market Analysis

13. Market Size of Smoking Cessation and Nicotine Addiction in Japan

14 Key Opinion Leaders’ View

15 SWOT Analysis

16 Unmet needs

17 Market Access and Reimbursement

18 Appendix

19 DelveInsight Capabilities

20 Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Smoking Cessation and Nicotine Addiction Market Size in the 7MM was ~USD 2,300 Million in 2023, estimated DelveInsight